Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot32610.32687/0869-866X-2020-28-4-541-547Научная статьяThe risk groups of infection with hepatitis С virus in conditionally healthy population of the Belgorod oblastMikhailovM. I.-JherebtzovaN. Yu.zherebtsova@bsu.edu.ruSchibrikE. V.-PivenV. I.-FetterV. V.-BerdinskikhL. V.-BelousovaO. N.-ZlobinaA. G.-RudenokO. P.-The Federal State Budget Educational Institution of Additional Professional Education “The Russian Medical Academy of Continuous Professional Education” of Minzdrav of RussiaThe Federal State Autonomous Educational Institution of Higher Education “The Belgorod State National Research Institute”The Department of Health Care and Social Care of Population of the Belgorod OblastThe Federal Budget Health Care Institution “The Center of Hygiene and Epidemiology in Belgorod Oblast”The Oblast State Budget Health Care Institution “The Belgorod Oblast Station of Blood Transfusion”The Oblast State Clinical Health Care Institution “The Hospital for Wars Veterans”1512202028454154706042021Copyright © 2020,2020The purpose of study was to establish risk group on hepatitis C in conditionally healthy population of the Belgorod oblast. Total 2025 conditionally healthy inhabitants aged between 1 and 99 were surveyed and serum samples from them were tested. There were eight age groups: 1-14 years (12.3%), 15-19 years (13.1%), 20-29 years (12.7%), 30-39 years (12.8%), 40-49 years (12.8%), 50-59 years (11.8%), 60-69 years (8.6%) and over 70 years of age (15.7%). Overall, 44.6% of the examined persons were male. 41.3% (ranging from 6.5 to 72.1%) of respondents reported surgery in their anamnesis, 5.1% (ranging from 0.8 to 12.6%) had blood/blood products transfusion, 10.3% (ranging from 1.7 to 57.9%) ear/nose piercing and 2.96% (ranging from 0.8 to 6.6%) tattoos. There were no people who injected drugs. The piercing was significantly higher in age groups 15-19 years and 20-29 years than other age groups (p-value<0.05). The tattoos were significantly higher in group of 70 years and older than in age groups 15-19 years, 30-39 years and 40-49 years (p-value<0.05). Anti-HCV antibodies were detected using third-generation enzyme-linked immunosorbent assay (“IFA-ANTI-HCV”, Nizhny Novgorod). The HCV RNA was tested with RT-PCR. The Anti-HCV was detected in 22 persons (1.1%), 77.3% out of them were older than 53 year and they were born prior to 1965. The Anti-HCV were significantly higher for the people over 70 years of age than in the age groups of 1-14 years, 15-19 years, 30-39 years and 40-49 years (p-value<0.05). The 2.65% of the examined persons were older 53 years had anti-HCV. Only 0.36% of anti-HCV were found in the young age groups of the examined persons who were born after 1965, the percentage was significantly lower than in older age groups (p-value<0.05). The 16 people had RNA-HCV and 87.5% persons were born in or before 1965. There was one person with genotype 3a (age group 30-39 years), 15 persons with genotype 1b (fourteen out of them were older 53 years and one person was in the age group 20-29 years. The study established that risk age group are inhabitants born before 1965 in Belgorod region. It can be taken into account in regional hepatitis С screening programs.anti-HCVRNA-HCVrisk factorrisk groupгепатит Санти-ВГСРНК ВГСфактор рискагруппа рискаhepatitis С1.Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: WHO; 2016.2.Global hepatitis report 2017. Geneva: WHO; 2017.3.Soriano V., Young B., Reau N. Report from the international conference on viral hepatitis - 2017. AIDS Rev. 2017;19:1-13.4.Cortesi P. A., Barca R., Giudicatti G., Mossini S., Ciaccio A., Iannazzo S. Economic evaluations of HCV screening in the direct-acting antivirals era. Aliment. Pharmacol. Ther. 2019;49(9):1126-33.5.Chemaitelly H., Mahmud S., Kouyoumjian S. P., Al-Kanaani Z., Hermez J. G., Abu-Raddad L. J. Who to test for hepatitis C virus in the Middle East and North Africa?: pooled analyses of 2,500 prevalence measures, including 49 million tests. Hepatol. Communicat. 2019;3(3):325-39.6.Вирусные гепатиты в Российской Федерации. Аналитический обзор. Выпуск 8. СПб.: ФБУН НИИЭМ имени Пастера; 2011.7.Yi S., Mun P., Chhoun P., Chann N., Tuot S., Mburu G. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. Harm Reduct. J. 2019;16:29.8.Smith B. D., Morgan R. L., Beckett G. A., Beckett G. A., Falck-Ytter Y., Holtzman D., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm. Rep. 2012;61(RR-4):1-32.9.Лекция от экспертов CMD № 2. Гепатит C: на пути от пандемии к элиминации. Режим доступа: https://www.youtube.com/watch? v=qmEg4gkve-M (дата обращения 21.06.2019).10.Matheï C. Wollants E., Verbeeck J., van Ranst M., Robaeys G., van Damme P. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur. J. Clin. Microbiol. Infect. Dis. 2005;24:514-22.11.Shepard C. W., Finelli L., Alter M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005;5:558-67.12.Boghdadi I. M. Korah T. E. M., Shayeb E. S. I. E., Marzouky E. A. M. Intrafamilial spread of hepatitis C virus in low socioeconomic population, Menoufiya Governorate. Nat. Sci. 2014;12(11):9-12.13.Insua J. T., Flaherty M. E. O., Silva M. Hepatitis C Virus (HCV) prevalence and risk of unsafe parenteral practices in Derqui, Argentine. Gastroenterol. Hepatol. 2017;6(1):00184.14.Соболева Н. В., Карлсен А. А., Кожанова Т. В., Кичатова В. С., Клушкина В. В., Исаева О. В. Распространенность вируса гепатита С среди условно здорового населения Российской Федерации. Журнал инфектологии. 2017;9(2):56-64.15.Altindis M., Demiray T., Köroglu M., Atasoy A. R., Kesli R., Tosun S. Hepatitis C testing among adults born between 1945 and 1965 in Turkey: a multicentre study. Cent. Eur. J. Public. Health. 2018;26(2):83-6.16.Rifat-uz-Zaman. Prevalence of hepatitis B and hepatitis C viruses in human urban population of Bahawalpur district, Pakistan. J. Med. Sci. 2006;6:367-73.17.Mohlman M. K., Saleh D. A., Ezzat S., Abdel-Hamid M., Korba B., Shetty K. Viral transmission risk factors in an Egyptian population with high hepatitis C prevalence. BMC Public Health. 2015;15:1030.18.Amin J., Gidding H., Gilbert G., Backhouse J., Kaldor J., Dore G. Hepatitis C prevalence - a nationwide serosurvey. Commun. Dis. Intell. 2004;28(4):517-21.19.Gonzalez R., Soza A., Hernandez V., Perez R. M., Alvarez M., Morales A., et al. Incidence and prevalence of hepatitis C virus infection in Chile. Ann. Hepatol. 2005;4(2):127-30.20.Daw M. A., El-Bouzedi A. Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey. BMC Infect. Dis. 2014;14:17.21.Toyoda H., Kumada T., Takaguchi K., Shimada N., Tanaka J. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol. Infect. 2014;142:2624-8.22.Aydemir Ö., Demiray T., Koroglu M., Ciftci I. H., Ozbek A., Altindis M. Hepatitis C prevalence in different age groups; people over 50 years of age may receive one-time testing for anti-HCV. Viral Hepat. J. 2015;21(2):40-3.